Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018;20(9):E841-848. doi:
10.1001/amajethics.2018.841.
There are at least two considerations here: the patient’s perception of a physician’s empathic expression and the physician’s level of comfort with expressing empathy and attending to patients’ emotions.
AMA J Ethics. 2015;17(2):111-115. doi:
10.1001/virtualmentor.2015.17.2.ecas1-1502.